JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2020, 69(4):151-162 | DOI: 10.36290/csf.2020.023

Vaccines from the perspective of a pharmacist

Aleš Franc
Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno

The field of development, production and safety of vaccines has recently come under the public eye. The aim of this review article is not to provide comprehensive information on the development and production of vaccines, which would not be possible even in a limited space. Its purpose is to outline a brief overview of the principles, development, and production of basic types of vaccines and point out the benefits and risks from the perspective of a pharmacist. He can participate not only in basic research, but his role is mainly in the formulation of a dosage form, registration of a vaccine, its distribution, and educational activities towards the lay and professional public.

Keywords: vaccine; research; development; production; safety

Received: June 25, 2020; Accepted: July 1, 2020; Published: April 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Franc A. Vaccines from the perspective of a pharmacist. Čes. slov. farm. 2020;69(4):151-162. doi: 10.36290/csf.2020.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vaccine. News Medical Life Sciences. https://www.news-medical.net/condition/Vaccine (15. 3. 2020).
    2. Lollini P. L., Forni G. Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol. Immun. 2002; 51, 409-416. Go to original source... Go to PubMed...
    3. Stanley A. P., Walter A. O. Paul A. O. Vaccines: Elsevier Health Sciences 2008.
    4. Dao Z. History of Chinese martial arts: DeepLogic 1985.
    5. Trebichaský I. Lži a mýty o očkování. Živa 2016; 3, LIII-LV.
    6. Ong E., He Y., Yang Z. Epitope promiscuity and population coverage of Mycobacterium tuberculosis protein antigens in current subunit vaccines under development. Infect. Genet. Evo. I. 2020; 8, 104186. Go to original source... Go to PubMed...
    7. Věda přináší neuvěřitelné množství překvapení. Zdravotnictví a medicína. https://zdravi.euro.cz/rozhovory/predstavujeme/445824 (27. 8. 2012).
    8. Letos se budou proti vzteklině vakcinovat lišky naposled. Tisková zpráva. SVS ČR. https://www.svscr.cz/letos_se_budou_proti_vztekline (14. 1. 2009).
    9. Goodchild L. Could dissolvable microneedles replace injected vaccines? Mater. Today 2015; 18, 419-420. Go to original source...
    10. Giersing B. K., Vekemans J, Nava S, Kaslow D. C., Moorthy V. WHO Product development for Vaccines Advisory Committee. Vaccine 2019; 50, 7315-7327. Go to original source... Go to PubMed...
    11. Petrová M. Očkování v České republice. Tempus medicorum - Farmakoterapeutické informace. Časopis ČLK 2015; 3-7.
    12. Cheng D. R., Perrett K. P., Choo S., Danchin M., Buttery J. P., Crawford N. W. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013. Vaccine 2015; 33, 1602-1607. Go to original source... Go to PubMed...
    13. Minor P. D. Live attenuated vaccines: historical successes and current challenges. Virology 2015; 479, 379-392. Go to original source... Go to PubMed...
    14. Fusek M., Káš J., Ruml T. Bioléčiva. Praha: Vydavatelství VŠCHT 2008.
    15. Ronald W. E. New Vaccine Technologies. CRC Press 2001.
    16. BCG vaccine: WHO position paper. WER 2004; 79, 25-40.
    17. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. WHO position paper. WER 2003; 78, 241-252.
    18. Measles vaccines: WHO position paper. WER 2009; 35, 349-360.
    19. Rotavirus vaccines: an update. WER 2009; 84, 533-538.
    20. Yellow fever vaccine: WHO position paper. WER 2003; 78, 349-360.
    21. Inactivated whole-cell (killed antigen) vaccines: types of vaccines and adverse reactions. WHO. https://vaccine-safety-training.org/inactivated-whole-cell-vaccines.html (15. 6. 2020).
    22. Stauffer F., El-Bacha T., Da Poian A. T. Advances in the development of inactivated virus vaccines. Recent Pat. Antiinfect. Drug Discov. 2006; 291-296. Go to original source... Go to PubMed...
    23. Piet M. P., Chin S., Prince A. M., Brotman B., Cundell A. M., Horowitz B. The use of tri(N-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 1990; 30, 591-598. Go to original source... Go to PubMed...
    24. Danihelkova H., Zavadova H. Disruption of influenza virus A by diethyl ether-Tween and tri-N-butyl phosphate-Tween mixtures. Acta Virol. 1984; 28, 26-32.
    25. Gao X., Zhao D., Zhou P., Zhang L., Li M., Li W., Zhang Y., Wang Y., Liu X. Characterization, pathogenicity and protective efficacy of a cell culture-derived porcine deltacoronavirus. Virus research 2020; 2, 197955. Go to original source... Go to PubMed...
    26. Pertussis vaccine: WHO position paper. WER 2005; 80, 29-40.
    27. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. WER 2003; 78, 241-252.
    28. Palache A. M., Brands R., Scharrenburg G. V. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 1997; 176 (Suppl 1), S20-S23. Go to original source... Go to PubMed...
    29. Möller J., Kraner M. E., Burkovski A. Proteomics of Bordetella pertussis whole-cell and acellular vaccines. BMC Res. Notes 2019; 12, 329. Go to original source... Go to PubMed...
    30. Hepatitis B vaccines: WHO position paper. WER 2009; 84, 405-420.
    31. de Greeff S. C., Sanders E. A., de Melker H. E., van der Ende A., Vermeer P. E., Schouls L. M. Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk. NTvG 2007; 151, 1454.
    32. Haemophilus influenzae type b conjugate vaccines: WHO position paper. WER 2006; 81, 445-452.
    33. Pneumococcal conjugate vaccine for childhood immunization: WHO position paper. WER 2007; 82, 93-104.
    34. van de Witte S. V., Nauta J., Giezeman-Smits K. M., de Voogd J. M. Trivalent inactivated subunit influenza vaccine Influvac®: 30-year experience of safety and immunogenicity. Trials Vaccinol. 2012; 1, 42-48. Go to original source...
    35. Beran J, Havlík J. Chřipka. Klinický obraz, prevence, léčba, 2. rozšířené vydání. Praha: Maxdorf 2005.
    36. Even-Or O., Avniel-Polak, S., Barenholz Y., Nussbaum G. The cationic liposome CCS/C adjuvant induces immunity to influenza independently of the adaptor protein MyD88. Human Vaccines & Immunotherapeutics 2020; 1-9. Go to original source... Go to PubMed...
    37. Spila-Alegiani S., Salmaso S., Rota M. C., Tozzi A. E., Raschetti R. Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Vaccine 1999; 17, 1898-1904. Go to original source... Go to PubMed...
    38. Broder K. R., Cortese M. M., Iskander J. K., Kretsinger K, Slade B. A., Brown K. H., Mijalski C. M., Tiwari T, Weston E. J., Cohn A. C., Srivastava P. U. Preventing tetanus, diphtheria, and pertussis among adolescents; use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006; 55, PR3. Go to original source...
    39. Jones R. G., Liu, Y., Rigsby P., Sesardic D. An improved method for development of toxoid vaccines and antitoxins. J Immunol. Methods 2008; 337, 42-48. Go to original source... Go to PubMed...
    40. Sato R., Fintan B. Effect of cash incentives on tetanus toxoid vaccination among rural Nigerian women: a randomized controlled trial. Hum. Vaccin Immunother. 2020; 16, 1181-1188. Go to original source... Go to PubMed...
    41. Tetanus vaccine: WHO position paper. WER 2006; 81,197-208.
    42. Diphtheria vaccine: WHO position paper. WER 2006; 81, 21-32.
    43. Patzer E. J., Nakamura G. R., Hershberg R. D., Gregory T. J., Crowley C, Levinson A. D., Eichberg J. W. Cell culture derived recombinant HBsAg is highly immunogenic and protects chimpanzees from infection with hepatitis B virus. Bio/technology 1986; 7, 630-636. Go to original source...
    44. Zhao Q., Wanga Y, Freedb D., Fub T. M., Gimeneza J. A., Sitrina R. D., Washabaugh M. W. Maturation of recombinant hepatitis B virus surface antigen particles. Hum. Vacc. 2006; 4, 174-180. Go to original source... Go to PubMed...
    45. Kazi A, Ismail C. M., Amilda A. A., Chuah C, Leow C. H., Lim B. H., Singh K. K., Leow C. Y. Designing and evaluation of an antibody-targeted chimeric recombinant vaccine encoding Shigella flexneri outer membrane antigens. Infect. Genet. Evol. 2020; 7, 104176. Go to original source... Go to PubMed...
    46. Hernández-Bernal F., Aguilar-Betancourt A., Aljovin V., Arias G., Valenzuela C., Perez de Alejo K., Hernández K., Oquendo O., Figueredo N., Figueroa N., Musacchio A. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults. Human Vacc. 2011; 10, 1026-1036. Go to original source... Go to PubMed...
    47. Cutts F. T., Franceschi S., Goldie S., Castellsague X. D., De Sanjose S., Garnett G., Markowitz, L. Human papillomavirus and HPV vaccines: a review. Bull. World Health. Organ. 2007; 85, 719-726. Go to original source... Go to PubMed...
    48. Josefsberg J. O., Buckland B. Vaccine process technology. Biotechnol. Bioeng. 2012; 109, 1443-1460. Go to original source... Go to PubMed...
    49. Li Y., Cao H., Dao, N., Luo Z., Yu H., Chen Y., Chen, X. High-throughput neuraminidase substrate specificity study of human and avian influenza A viruses. Virology 2011; 415, 12-19. Go to original source... Go to PubMed...
    50. Ura T., Okuda K., Shimada M. Developments in viral vector-based vaccines. Vaccines 2014; 3, 624-641. Go to original source... Go to PubMed...
    51. Sutter G., Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 2003; 3, 263-271. Go to original source... Go to PubMed...
    52. Shanmugaraj B., Priya L. B., Mahalakshmi B., Subbiah S., Hu, R. M., Velmurugan B. K., Baskaran, R. Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy. Life Sci. 2020; 117550. Go to original source... Go to PubMed...
    53. Srivastava I. K., Liu M. A. Gene vaccines. Ann. Intern. Med. 2003; 138, 550-559. Go to original source... Go to PubMed...
    54. van Rompay K. K., Keesler R. I., Ardeshir A., Watanabe J., Usachenko J., Singapuri A., Cruzen C., Bliss-Moreau E., Murphy A. M., Yee JL, Webster H. DNA vaccination before conception protects Zika virus-exposed pregnant macaques against prolonged viremia and improves fetal outcomes. Sci. Transl. Med. 2019; 18, 523. Go to original source... Go to PubMed...
    55. Felber B. K., Pavlakis G. N. HIV vaccine: better to start together? The Lancet HIV 2019; 11, e724-725. Go to original source... Go to PubMed...
    56. Gaudinski M. R., Houser K. V., Morabito K. M, Hu Z., Yamshchikov G., Rothwell R. S., Berkowitz N., Mendoza F., Saunders J. G., Novik. L., Hendel C. S. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 2018; 391, 552-562. Go to original source... Go to PubMed...
    57. Salyaev R. K., Rekoslavskaya N. I. Plant-Based Peroral Vaccines. In Multifunctional Systems for Combined Delivery. Biosensing and Diagnostics 2017; 1, 193-210. Go to original source...
    58. Streatfield S. J., Howard J. A. Plant-based vaccines. Int. J. Parasitol. Parasites 2003; 33, 479-493. Go to original source... Go to PubMed...
    59. Chan H. T., Daniell H. Plant-made oral vaccines against human infectious diseases - are we there yet? Plant Biotechnol. J. 2015; 13, 1056-1070. Go to original source... Go to PubMed...
    60. Takeyama N., Kiyono H., Yuki Y. Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Ther Adv Vaccines 2015; 3, 139-154. Go to original source... Go to PubMed...
    61. Mak T. W., Saunders M. E., Jett B. D. Primer to the immune response: Academic Cell 2014.
    62. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev. Vaccines 2007; 6, 381-390. Go to original source... Go to PubMed...
    63. Fuenmayor J., Gòdia F., Cervera L. Production of virus-like particles for vaccines. New biotech. 2017; 39, 174-180. Go to original source... Go to PubMed...
    64. Roldao A, Silva A. C., Mellado M. C., Alves P. M., Carrondo M. J. Viruses and virus-like particles in biotechnology: fundamentals and applications. Comprehensive biotechnology 2017; 1, 633-656. Go to original source...
    65. Ludwig C., Wagner R. Virus-like particles - universal molecular toolboxes. Curr. Opin. Biotechnol. 2007; 18, 537-545. Go to original source... Go to PubMed...
    66. Skwarczynski M., Toth I. Micro-and nanotechnology in vaccine development: William Andrew 2016.
    67. Cook I. F. Evidence based route of administration of vaccines. Hum. Vacc. 2008; 4, 67-73. Go to original source... Go to PubMed...
    68. Sheets R. L. Opinion on adventitious agents testing for vaccines: Why do we worry so much about adventitious agents in vaccines? Vaccine 2013; 31, 2791-2795. Go to original source... Go to PubMed...
    69. Thomassen Y. E., van Sprang E. N., van der Pol L. A., Bakker W. A. Multivariate data analysis on historical IPV production data for better process understanding and future improvements. Biotechnology and bioeng 2010; 107, 96-104. Go to original source... Go to PubMed...
    70. Aiyer-Harini P, Ashok-Kumar H. G., Kumar G. P., Shivakumar N. An overview of immunologic adjuvants. J. Vaccines Vacci. 2013; 4, 1000167.
    71. Goto N., Kato H., Maeyama J. I., Eto K, Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 1993; 11, 914-918. Go to original source... Go to PubMed...
    72. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002; 31, 34-39. Go to original source... Go to PubMed...
    73. Petrovsky N., Cooper P. D. Carbohydrate-based immune adjuvants. Expert Rev Vaccines 2011; 10, 523-537. Go to original source... Go to PubMed...
    74. Kino Y. Vaccine excipients. Nihon. Rinsho. 2008; 66, 1933-1937.
    75. Excipients in vaccines per 0.5 mL dose. IVS. John Hoppkins Bluumberg School and Public. http://www.vaccinesafety.edu/components-Excipients.htm (15. 6. 2002).
    76. Wiedermann-Schmidt U., Maurer W. Relevance of additives and adjuvants in vaccines for allergic and toxic side effects. Wien. Klin. Wochenschr. 2005; 117, 510-519. Go to original source... Go to PubMed...
    77. Prausnitz M. R., Langer R. Transdermal drug delivery. Nature biotech. 2008; 26, 1261. Go to original source... Go to PubMed...
    78. Toyoda M., Hama S, Ikeda Y, Nagasaki Y, Kogure K. Anti-cancer vaccination by transdermal delivery of antigen peptide-loaded nanogels via iontophoresis. Int. J. Pharm. 2015; 10, 110-114. Go to original source... Go to PubMed...
    79. Quinn H. L., Kearney M. C., Courtenay A. J., McCrudden M. T., Donnelly R. F. The role of microneedles for drug and vaccine delivery. Expert Opin. Drug Deliv. 2014; 11, 1769-1780. Go to original source... Go to PubMed...
    80. Mishra D., Dubey V., Asthana A., Saraf D. K., Jain N. K. Elastic liposomes mediated transcutaneous immunization against Hepatitis B. Vaccine 2006; 24, 4847-4855. Go to original source... Go to PubMed...
    81. Gogoll K., Stein P., Lee K. D., Arnold P., Peters T., Schild H., Radsak M., Langguth P. Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization. Cell. Immunol. 2016; 308, 35-43. Go to original source... Go to PubMed...
    82. Mahor S., Rawat A., Dubey P. K., Gupta P. N., Khatri K., Goyal A. K. Cationic Transfersomes based topical genetic vaccine against hepatitis B. Int. J. Pharm. 2007; 340: 13-19. Go to original source... Go to PubMed...
    83. Pielenhofer J., Sohl J., Windbergs M., Langguth P., Radsak M. P. Current progress in particle-based systems for transdermal vaccine delivery. Front. Immunol. 2020; 11, 266. Go to original source... Go to PubMed...
    84. Nemes E., Geldenhuys H., Rozot V., Rutkowski K. T., Ratangee F., Bilek N., Mabwe S., Makhethe L., Erasmus M., Toefy A., Mulenga H. Prevention of M. tuberculosis infection with H4: IC31 vaccine or BCG revaccination. N. Engl. J. Med. 2018; 379,138-149. Go to original source... Go to PubMed...
    85. Bragazzi N. L, Orsi A., Ansaldi F., Gasparini R., Icardi G. Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview. Hum. Vaccin Immunother. 2016; 12, 2616-2627. Go to original source... Go to PubMed...
    86. Partidos C. D. Intranasal vaccines: forthcoming challenges. Pharm. Sci. Technol. Today 2000; 8, 273-281. Go to original source... Go to PubMed...
    87. Davis S. S. Nasal vaccines. Adv. Drug Deliv. 2001; 51, 21-42. Go to original source... Go to PubMed...
    88. Heurtault B., Frisch B., Pons F. Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin Drug Deliv. 2010; 7, 829-844. Go to original source... Go to PubMed...
    89. Partidos C. D. Intranasal vaccines: forthcoming challenges. Pharm. Sci. Technol. Today 2000; 8, 273-2781. Go to original source... Go to PubMed...
    90. Hu K. F., Lövgren-Bengtsson K., Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug Deliv. Rev. 2001; 51, 149-159. Go to original source... Go to PubMed...
    91. Slütter B., Bal S, Keijzer C., Mallants R., Hagenaars N., Que I., Kaijzel E., van Eden W., Augustijns P., Löwik C., Bouwstra J. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 2010; 38, 6282-6291. Go to original source... Go to PubMed...
    92. Vaccines licensed for use in the United States, FDA. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states (15. 6. 2020).
    93. Wright A. E. Notes on the treatment of furunculosis, sycosis, and acne by the inoculation of a staphylococcus vaccine: and generally on the treatment of localised bacterial invasions by therapeutic inoculations of the corresponding bacterial vaccines. Lancet 1902; 159: 874-884. Go to original source...
    94. Bakker W. A., Thomassen Y. E., van't Oever A. G, Westdijk J., van Oijen M. G., Sundermann L. C., van't Veld P., Sleeman E., van Nimwegen F. W., Hamidi A, Kersten G. F. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011; 41, 7188-7196. Go to original source... Go to PubMed...
    95. Ramirez J. E., Sharpe L. A., Peppas N. A. Current state and challenges in developing oral vaccines. Adv. Drug Deliv. Rev. 2017; 114, 116-131. Go to original source... Go to PubMed...
    96. Arora R. Advances in niosome as a drug carrier: a review. Asian J. Pharm. 2016; 9, 29-39.
    97. Gould-Fogerite S., Mannino R. J. Mucosal and systemic immunization using cochleate and liposome vaccines. J. Liposome Res. 1996; 2, 357-379. Go to original source...
    98. Jain S., Khomane K. K., Jain A., Dani P. Nanocarriers for transmucosal vaccine delivery. Curr. Nanosci. 2011; 7, 160-177. Go to original source...
    99. Ramirez J. E., Sharpe L. A., Peppas N. A. Current state and challenges in developing oral vaccines. Adv. Drug Deliv. Rev. 2017; 15, 116-131. Go to original source... Go to PubMed...
    100. Narasimhan B., Goodman J. T., Vela Ramirez J. E. Rational design of targeted next-generation carriers for drug and vaccine delivery. Annu. Rev. Biomed. Eng. 2016; 18, 25-49. Go to original source... Go to PubMed...
    101. Zhu Q., Talton J., Zhang G., Cunningham T., Wang Z., Waters R. C., Kirk J, Eppler B., Klinman D. M., Sui Y, Gagnon S. Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nature Med. 2012; 18,1291-1296. Go to original source... Go to PubMed...
    102. Marco I., Feyerabend F., Willumeit-Römer R., vVan der Biest O. Degradation testing of Mg alloys in Dulbecco's modified eagle medium: Influence of medium sterilization. Mater. Sci. Eng. C. 2016; 62, 68-78. Go to original source... Go to PubMed...
    103. Vogel F. R., Powell M. F. A compendium of vaccine adjuvants and excipients. Vaccine Design. Boston, MA: Springer 1995. Go to original source...
    104. Rhee J. H. Current and New Approaches for Mucosal Vaccine Delivery. In Mucosal Vaccines. Academic Press 2020.
    105. Mort M., Baleta A., Destefano F. Vaccine safety basics learning manual. WHO Press, Switzerland 2013.
    106. Výroba léčivých přípravků biologického původu. Doplněk 2. SÚKL 2003. http://www.sukl.cz/leciva/doplnek-2
    107. Mascola J. R., Fauci A. S. Novel vaccine technologies for the 21st century. Nat. Rev. Immunol. 2020; 2, 87-88. Go to original source... Go to PubMed...
    108. Paules C. I., Sullivan S. G., Subbarao K., Fauci A. S. Chasing seasonal influenza - the need for a universal influenza vaccine. N. Engl. J. Med. 2018; 378, 7-9. Go to original source... Go to PubMed...
    109. Hewajuli D. A., Dharmayanti N. I. Efficacy, mechanism and antiviral resistance of neuraminidase inhibitors and adamantane against avian influenza. ICARD 2019; 29, 61-74. Go to original source...
    110. Andrews, S. F., Graham, B. S., Mascola, J. R., McDermott, A. B. Is it possible to develop a "universal" influenza virus vaccine? Cold Spring Harbor Perspectives in Biology 2018; 10, a029413. Go to original source... Go to PubMed...
    111. Bloom, B. R. New promise for vaccines against tuberculosis. N. Engl. J. Med. 2018; 379, 1672-1674. Go to original source... Go to PubMed...
    112. Gursel M., Gursel I. Is global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic? Med. Hypotheses 2020; 6, 109707. Go to original source...
    113. Bohmwald K., Espinoza J. A., Pulgar R. A., Jara E. L., Kalergis A. M. Functional impairment of mononuclear phagocyte system by the human respiratory syncytial virus. Front. Immunol. 2017; 27, 1643. Go to original source... Go to PubMed...
    114. Crank M. C., Ruckwardt T. J., Chen M., Morabito K. M., Phung E., Costner P. J., Holman L. A., Hickman S. P., Berkowitz N. M., Gordon I. J., Yamshchikov G. V. A proof of concept for structure-based vaccine design targeting RSV in humans. Science 2019; 6452, 505-509. Go to original source... Go to PubMed...
    115. Malaria, Key facts. WHO 14. January 2020. https://www.who.int/news-room/fact-sheets/detail/malaria
    116. New estimates of malaria deaths: concern and opportunity. Lancet 201; 9814, 385.
    117. Thera M. A., Plowe C. V. Vaccines for malaria: how close are we? Annu. Rev. Med. 2012; 63, 345-357. Go to original source... Go to PubMed...
    118. Global HIV & AIDS statistics - 2019 fact sheet, UNADIS. https://www.unaids.org/en/resources/fact-sheet (15. 6. 2009).
    119. Phillips M. A., Goldberg D. E. Toward a chemical vaccine for malaria. Science 2018; 6419, 1112-1118. Go to original source... Go to PubMed...
    120. van Regenmortel M. H. HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design: A review of 20 years of research: Springer Nature 2019. Go to original source...
    121. Eroshenko N., Gill T., Keaveney M. K., Church G. M., Trevejo J. M., Rajaniemi H. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nature Biotech. 2020; 38, 789-791. Go to original source... Go to PubMed...
    122. Gursel M., Gursel M. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? Allergy 2020; 7, 1815-1819. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.